Switch Language
Alt tag
ESC CONGRESS 2021

Learn about Bayer-sponsored activities at ESC Congress 2021:
Inform yourself, follow up & access the content!

arrow

 

    Bayer logo

    Industry Q&A Symposium   |   Session number: 2000

    Evolving cardiovascular risk: Your patient’s past, present and future

    Saturday, 28 August, 13:00–13:45 CEST
    Faculty: Manesh Patel, Roxana Mehran, Craig Coleman, Reinhold, Kreutz, Rónán Collins

    The session highlighted the dynamic risk of thrombotic events in patients with atrial fibrillation and showed how different patient risk factors affect optimal treatment choice. Furthermore, the importance of continuous benefit-risk assessment was demonstrated to ensure patients receive the best possible protection.

    Agenda

    13:00-13:10
    Introduction to our patient

    Manesh Patel and Roxana Mehran

     

    13:10-13:20
    Patients with atrial fibrillation and diabetes

    Manesh Patel and Craig Coleman

     

    13:20-13:30
    Consider the kidney: New data on patients with atrial fibrillation and renal impairment

    Manesh Patel and Reinhold Kreutz

     

    13:30-13:35
    Maintaining protection: Longitudinal benefit–risk assessment in older patients

    Manesh Patel and Rónán Collins

     

    13:35-13:45
    Live Q&A

    Manesh Patel, Craig Coleman and Reinhold Kreutz

    See Agenda Details Access ESC Congress 2021 Session Page

    Watch the Bayer-sponsored symposium at ESC Congress 2021:

    Video title

    YYMMDD Author/Uploaded by

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

    Bayer logo

    Exclusive Live Symposium   |   Session number: 2001

    New therapies for patients following a worsening HF event

    Saturday, 28 August, 15:00-15:30 CEST
    Faculty: Paul Armstrong, Carolyn Lam, Burkert Pieske, Michele Senni

    The symposium discussed the high event rates and unmet need in patients following a worsening HF event. The clinical benefits of vericiguat in this patient population and its potential role in the current treatment landscape have been reviewed by the faculty.

    Agenda

    15:00-15:05

    Welcome and introduction

    Paul Armstrong (Co-chair) (Edmonton, CA)

     

    15:05-15:12

    Therapeutic advances: A new sGC stimulator for patients following a worsening HF event

    Burkert Pieske (Berlin, DE)

     

    15:12-15:17

    Top tips for practical patient management

    Michele Senni (Bergamo, IT)

     

    15:17-15:27

    Live Q&A

    Carolyn Lam, Paul Armstrong, Michele Senni, Burkert Pieske

     

    15:27-15:30

    Summary and close

    Carolyn Lam (Co-chair) (Singapore)

    See Agenda Details Watch session on ESC website on demand

    Teaser video:

    Video title

    YYMMDD Author/Uploaded by

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

    Bayer logo

    Industry Q&A Symposium   |   Session number: 2002

    What's next for your patients following a worsening HF event?

    Sunday, 29 August 2021, 13:00 - 13:45 CEST
    Faculty: Carolyn Lam, Faiez Zannad, Javed Butler, Ewa Jankowska

     

    The Q&A symposium is highlighted the unmet need in patients with worsening HF and the poor prognosis following a worsening HF event. The key outcomes from the VICTORIA trial and their impact on clinical practice was reviewed and clinical decision-making for the treatment of patients after a worsening HF event has been discussed.

    Agenda

    13:00-13:10

    Welcome and introduction

    Carolyn Lam (Co-chair) (Singapore)

     

    13:10-13:20

    VICTORIA in context: Deep dive into the latest data

    Javed Butler (Mississippi, US)

     

    13:20-13:35

    Live panel discussion: Managing the patient after a worsening HF event

    Carolyn Lam, Javed Butler, Faiez Zannad (Nancy, FR), Ewa Jankowska (Wrocław, PL)

     

    13:35-13:40

    Live Q&A

    All

     

    13:40-13:45

    Summary and close

    Faiez Zannad (Co-chair)

    See Agenda Details Watch session on ESC website on demand

    Teaser video:

    Video title

    YYMMDD Author/Uploaded by

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

    Bayer logo

    Exclusive Live Symposium   |   Session number: 2003

    Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

    Sunday, 29 August 2021, 16:50 - 17:20 CEST
    Faculty: Stefan Anker, Michele Senni, Gerasimos Filippatos

    The faculty described the impact of Mineralocorticoide Receptor Overactivation on cardiorenal morbidity in patients with CKD and T2D and recognised the need for novel treatments for the management of CKD in patients with T2D, including those that target MR overactivation. The symposium helped to understand how nonsteroidal MRAs can improve cardiorenal outcomes in patients with CKD in T2D.

    Agenda

    16:50-16:52

    Welcome and introductions

    Stefan Anker (Berlin, DE)

     

    16:52-17:00

    How to improve cardiorenal outcomes in patients with CKD and T2D?

    Michele Senni (Bergamo, IT)

     

    17:00-17:15

    Insights into the cardiovascular and kidney benefits of MR antagonism: Insights from the FIGARO-DKD and FIDELIO-DKD trials

    Gerasimos Filippatos (Athens, GR)

     

    17:15-17:20

    Live Q&A

    Stefan Anker (Berlin, DE)

     

    17:20

    Summary and close

    Stefan Anker (Berlin, DE)

    See Agenda Details Watch session on ESC website on demand

    Teaser video:

    Video title

    YYMMDD Author/Uploaded by

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

    Join more than 1.500 of your peers to stay up to date and receive highlights from the ESC Congress 2021.

    Sign up now!

    Alt tag

    Click here and follow our twitter channel for all updates around vascular health, venous thrombosis, atrial fibrillation and stroke prevention.

    PP-FINE-ALL-0182-1

    Updated date: 05/08/2021